Evaluation of the potential for QTc prolongation in patients with solid tumors receiving nivolumab

[1]  David C. Smith,et al.  Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  R. Motzer,et al.  Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  G. Linette,et al.  Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. , 2015, The Lancet. Oncology.

[4]  F. Cappuzzo,et al.  Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. , 2015, The Lancet. Oncology.

[5]  M. Millenson,et al.  PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. , 2015, The New England journal of medicine.

[6]  D. Schadendorf,et al.  Nivolumab in previously untreated melanoma without BRAF mutation. , 2015, The New England journal of medicine.

[7]  D. Schadendorf,et al.  Nivolumab improved survival vs dacarbazine in patients with untreated advanced melanoma , 2015, Journal of Translational Medicine.

[8]  T. Choueiri,et al.  QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors , 2014, British Journal of Cancer.

[9]  J. Infante,et al.  Clinical Impact of Checkpoint Inhibitors as Novel Cancer Therapies , 2014, Drugs.

[10]  E. Deeks.  Nivolumab: A Review of Its Use in Patients with Malignant Melanoma , 2014, Drugs.

[11]  David C. Smith,et al.  Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  J. Marier,et al.  Exposure–response analysis of pertuzumab in HER2-positive metastatic breast cancer: absence of effect on QTc prolongation and other ECG parameters , 2013, Cancer Chemotherapy and Pharmacology.

[13]  R. Shah,et al.  Cardiovascular Safety of Tyrosine Kinase Inhibitors: With a Special Focus on Cardiac Repolarisation (QT Interval) , 2013, Drug Safety.

[14]  H. Lu,et al.  Evaluation of the relationship between cetuximab therapy and corrected QT interval changes in patients with advanced malignancies from solid tumors , 2013, Cancer Chemotherapy and Pharmacology.

[15]  P. Sager,et al.  Electrocardiographic assessment for therapeutic proteins--scientific discussion. , 2010, American heart journal.

[16]  Ricardo Bolaños,et al.  QT interval prolongation: preclinical and clinical testing arrhythmogenesis in drugs and regulatory implications. , 2010, Current drug safety.

[17]  Wendy R. Sanhai,et al.  Assessing proarrhythmic potential of drugs when optimal studies are infeasible. , 2009, American heart journal.

[18]  L. S. Fridericia.  Die Systolendauer im Elektrokardiogramm bei normalen Menschen und bei Herzkranken , 2009 .

[19]  Liudmila Polonchuk,et al.  Scientific review and recommendations on preclinical cardiovascular safety evaluation of biologics. , 2008, Journal of pharmacological and toxicological methods.

[20]  D. Roden,et al.  Cellular basis of drug‐induced torsades de pointes , 2008, British journal of pharmacology.

[21]  R. Shah,et al.  Cardiac Repolarisation and Drug Regulation , 2007, Drug safety.

[22]  L. S. Fridericia,et al.  The Duration of Systole in an Electrocardiogram in Normal Humans and in Patients with Heart Disease * , 2003, Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc.

[23]  H. Bazett,et al.  AN ANALYSIS OF THE TIME‐RELATIONS OF ELECTROCARDIOGRAMS. , 1997 .